Immunosuppression by mesenchymal stromal cells: from culture to clinic
- PMID: 18474304
- DOI: 10.1016/j.exphem.2008.03.006
Immunosuppression by mesenchymal stromal cells: from culture to clinic
Abstract
Extensive in vitro studies have shown that multipotent mesenchymal stromal cells (MSC) can exert profound immunosuppressive effects via modulation of both cellular and innate immune pathways. Their ability to be readily isolated from a number of tissues and expanded ex vivo makes them attractive candidates for systemic immunosuppressive therapy. In this article, we will review recent experimental data on the mechanisms by which MSC inhibit the alloproliferative response and the clinical relevance for their potential use in hematopoietic stem cell transplantation, solid organ transplantation, and treatment of autoimmune diseases. While in vitro data consistently demonstrate the immunosuppressive capability of MSC, current studies in animals and humans suggest that MSC are less effective in producing systemic immunosuppression. Further mechanistic studies and randomized controlled trials using standardized cell populations are needed to define the optimal conditions for the use of MSC as immunotherapy.
Similar articles
-
Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype.Haematologica. 2005 Apr;90(4):516-25. Haematologica. 2005. PMID: 15820948
-
Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.Immunol Invest. 2008;37(1):29-42. doi: 10.1080/08820130701410223. Immunol Invest. 2008. PMID: 18214798
-
Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2005 May;11(5):321-34. doi: 10.1016/j.bbmt.2005.01.005. Biol Blood Marrow Transplant. 2005. PMID: 15846285 Review.
-
Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation.Blood Cells Mol Dis. 2008 Jan-Feb;40(1):25-32. doi: 10.1016/j.bcmd.2007.06.021. Epub 2007 Sep 14. Blood Cells Mol Dis. 2008. PMID: 17869550 Clinical Trial.
-
Therapeutic potential of genetically modified mesenchymal stem cells.Gene Ther. 2008 May;15(10):711-5. doi: 10.1038/gt.2008.35. Epub 2008 Mar 20. Gene Ther. 2008. PMID: 18356815 Review.
Cited by
-
Olfactory Ensheathing Cells: A Trojan Horse for Glioma Gene Therapy.J Natl Cancer Inst. 2019 Mar 1;111(3):283-291. doi: 10.1093/jnci/djy138. J Natl Cancer Inst. 2019. PMID: 30257000 Free PMC article.
-
Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially.PLoS One. 2010 Feb 2;5(2):e9016. doi: 10.1371/journal.pone.0009016. PLoS One. 2010. PMID: 20126406 Free PMC article.
-
Targeting dorsal root ganglia and primary sensory neurons for the treatment of chronic pain.Expert Opin Ther Targets. 2017 Jul;21(7):695-703. doi: 10.1080/14728222.2017.1328057. Epub 2017 May 16. Expert Opin Ther Targets. 2017. PMID: 28480765 Free PMC article. Review.
-
Stem cells as therapeutic vehicles for the treatment of high-grade gliomas.Neuro Oncol. 2012 Mar;14(3):256-65. doi: 10.1093/neuonc/nor204. Epub 2011 Dec 13. Neuro Oncol. 2012. PMID: 22166262 Free PMC article. Review.
-
Targeting dorsal root ganglia and primary sensory neurons for the treatment of chronic pain: an update.Expert Opin Ther Targets. 2023 Jul-Dec;27(8):665-678. doi: 10.1080/14728222.2023.2247563. Epub 2023 Aug 22. Expert Opin Ther Targets. 2023. PMID: 37574713 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources